KNOW THE RISK: MENINGOCOCCAL DISEASE CAN PROGRESS FAST AND BE FATAL1

  • An uncommon but serious bacterial infection caused by Neisseria meningitidis1,2
  • Symptoms can progress to death in as few as 24 hours1,3
  • Of those who contract meningococcal disease, between 10% and 15% die from complications despite appropriate antibiotic treatment2
  • About 11% to 19% of survivors suffer permanent sequelae, such as seizures/neurological problems, loss of limbs, kidney damage, hearing loss, skin scarring, and brain damage1,4,5

According to CDC, serogroup B caused the majority of all US meningococcal cases in patients 16-23 years of age from 2018 to 20226

Cases of Meningococcal Disease in the US by MenB Serogroup and MenACWY Serogroups and Other* Serogroups

Pie Chart displaying B = 43%; A, C, W, Y other* = 57%

n=165

*Other, nongroupable, unknown

As of 2022, CDC survey data showed the MenB vaccination rate among adolescents was low7

Only 29.4%

of 17-year-olds had received at least 1 dose of a MenB vaccine

ONLY 11.9% of 17-year-olds had received 2 doses or more of a MenB vaccine.7

Follow the CDC recommendation

CDC recommends a primary series for adolescents not at increased risk, aged 16-23 years (preferred age 16-18 years), based on shared clinical decision-making.8-10

One dose is not enough!

Your patients need more than 1 dose to complete a MenB vaccination series.9 Make sure your patients are fully vaccinated against MenB.

Vaccination may not protect all recipients.

Dose Icon

See the impact of MenB

Watch a real survivor story.

Complete the Vaccination Series >

CDC=Centers for Disease Control and Prevention; MenACWY=meningococcal serogroups A, C, W, and Y; MenB=meningococcal serogroup B.

INDICATION & IMPORTANT SAFETY INFO
INDICATION

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

  • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO
  • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO